# Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

> **NCT00877253** · PHASE1 · COMPLETED · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 18 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Genexol-PM 220mg/㎡, Carboplatin 5AUC
- **DRUG:** Genexol-PM 260mg/㎡, Carboplatin 5AUC
- **DRUG:** Genexol-PM 300mg/㎡, Carboplatin 5AUC

## Key facts

- **NCT ID:** NCT00877253
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877253, "Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00877253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*